A LacZ-based transgenic mouse for detection of somatic gene repair events in vivo

Gene Therapy
H D Nickerson, W H Colledge

Abstract

Somatic gene repair of disease-causing chromosomal mutations is a novel approach for gene therapy. This method would ensure that the corrected gene is regulated by its endogenous promoter and expressed at physiological levels in the appropriate cell types. A reporter mouse, Gtrosa26(tm1Col), was generated by targeting a mutated LacZ gene to the Rosa26 locus in mouse embryonic stem (ES) cells. The LacZ gene contains a G to A point mutation, resulting in a Glu to Lys amino-acid substitution at position 461, which abrogates enzymatic activity. The gene is expressed in ES cells, primary embryonic fibroblasts, and in all tissues examined in the adult mouse, including the lung, liver, kidney, spleen, heart, brain and smooth muscle. This transgenic mouse will allow testing of gene repair strategies in vivo and identification of which cell types can be successfully targeted by chromosomal gene repair. Although low levels of gene repair were achieved in the ES cells used to generate the Gtrosa26(tm1Col) mouse, preliminary attempts at gene repair in vivo were unsuccessful, thus highlighting the difficulties that will have to be overcome to get this approach to work.

References

Jan 1, 1991·Environmental and Molecular Mutagenesis·S W KohlerJ M Short
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J A GossenJ Vijg
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·M E DowtyJ A Wolff
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·B P ZambrowiczP Soriano
Jan 15, 1998·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Y XiangE B Kmiec
Apr 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·X MaoS H Orkin
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·B T KrenC J Steer
Nov 21, 2000·Human Gene Therapy·O Igoucheva, K Yoon
Mar 10, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·A ColosimoD C Gruenert
Mar 30, 2001·The Journal of Biological Chemistry·A D TagalakisJ S Owen
Apr 25, 2001·The Journal of Gene Medicine·E S ScottW H Colledge
Nov 1, 2001·Nature Genetics·R AwatramaniS Dymecki
Mar 2, 2002·The Journal of Biological Chemistry·Anatilde M González-GuerricoTomás A Santa-Coloma
Mar 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·Rachel B CervantesPeter J Stambrook
May 29, 2002·Gene Therapy·K K GonczD C Gruenert
May 29, 2002·Gene Therapy·P ThorpeD J Porteous

❮ Previous
Next ❯

Citations

Aug 1, 2006·Nature Biotechnology·Daniel G MillerDavid W Russell
Oct 13, 2005·Genetic Vaccines and Therapy·Asami InoIchizo Kobayashi
Feb 11, 2012·Expert Opinion on Biological Therapy·Ioannis PapaioannouJames S Owen
Feb 18, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nicole K PaulkMarkus Grompe
Apr 9, 2005·Gene Therapy·H Parekh-OlmedoE B Kmiec

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.